Chemokines and Epigenetics in Non-Small Cell Lung Cancer
Author Information
Author(s): Baird Anne-Marie, Gray Steven G., O'Byrne Kenneth J.
Primary Institution: Thoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College, Dublin, Ireland
Hypothesis
The expression of CXC (ELR+) chemokines and their receptors is regulated epigenetically in non-small cell lung cancer (NSCLC).
Conclusion
CXC (ELR+) chemokines are dysregulated in NSCLC, and their balance may be critical in the tumor microenvironment.
Supporting Evidence
- CXC (ELR+) chemokines are important in neo-vascularisation and metastasis.
- Histone deacetylase inhibitors can up-regulate CXCL8 in lung cancer cell lines.
- Expression of many chemokines was found to be downregulated in NSCLC tumors.
Takeaway
This study found that certain chemicals in lung cancer are not working properly, and changing how they are controlled might help treat the cancer better.
Methodology
The study examined the expression of CXC (ELR+) chemokines in NSCLC tumor samples and cell lines using RT-PCR and chromatin immunoprecipitation.
Potential Biases
Potential bias due to the limited sample size and specific patient demographics.
Limitations
The heterogeneity of tumor samples makes it difficult to draw definitive conclusions.
Participant Demographics
14 adenocarcinoma and 23 squamous cell carcinoma patients with early stage NSCLC.
Statistical Information
P-Value
p<0.01 for CXCL1 and CXCL2; p<0.05 for CXCR1.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website